Home > Insider Trading > Filing (0001209191-22-015917)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1652130	Intellia Therapeutics Inc.	NTLA	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1581992	Glenn Goddard	C/O Intellia Therapeutics, Inc. 40 Erie Street; Suite 130 Cambridge MA 02139	Evp, Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2022-01-01	3,062	$0.00	3,062	No	4	M	Direct
Common Stock	Disposition	2022-01-01	1,013	$112.24	2,049	No	4	S	Direct
Common Stock	Acquisiton	2022-03-01	12,720	$0.00	14,769	No	4	A	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	A	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Unit	Disposition	2022-01-01	3,062	$0.00	3,062	$0.00
Common Stock	Stock Option (right to buy)	Acquisiton	2022-03-01	12,720	$0.00	12,720	$79.85

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
9,188	2022-01-01	2031-03-02	No	4	M	Direct
12,720		2032-02-28	No	4	A	Direct

Footnotes

Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 1, 2022.
Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
On March 3, 2021, the reporting person was granted 12,250 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter.
This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.